DPHARMA | DUOPHARMA BIOTECH BHD

1.26 (-0.79%)

T-O (am): 0.000 (08:59:00)
Last updated: 17:00

Fundamental
Technical
Total Score

DPHARMA | DUOPHARMA BIOTECH BHD


iSaham Fundamental Trend

FCON: | Sharpe Ratio: | LTS:


Quarter Reports

Chart:

Select columns required and click "Update" to save your preferences

Ann. Date Qtr. Date Q FYE Revenue [M] PBT [M] NP [M] NPM DPS EPS R. QoQ R. YoY E. QoQ E. YoY TTM
EPS
Adj.
[M]
NP [M]
(adj)
NPM
(adj)
EPS
(adj)
E. QoQ
(adj)
E. YoY
(adj)
TTM EPS
(adj)
23 May 24 Q1 Mar 24 1 31 Dec 24 192.97 20.10 15.28 7.9% 0.00 1.59 15.2% 3.7% 79.7% 32.5%
22 Feb 24 Q4 Dec 23 4 31 Dec 23 167.50 7.03 8.50 5.1% 1.80 0.88 1.0% 10.2% 5.2% 50.5%
08 Nov 23 Q3 Sep 23 3 31 Dec 23 169.24 11.43 8.97 5.3% 0.00 0.93 1.0% 4.4% 28.5% 45.1%
24 Aug 23 Q2 Jun 23 2 31 Dec 23 167.52 16.52 12.54 7.5% 0.50 1.31 16.4% 7.8% 44.6% 23.1%
22 May 23 Q1 Mar 23 1 31 Dec 23 200.47 28.29 22.63 11.3% 0.00 2.38 31.9% 7.8% 31.9% 11.5%
23 Feb 23 Q4 Dec 22 4 31 Dec 22 151.96 15.35 17.16 11.3% 1.80 1.80 14.2% 4.5% 5.0% 9.2%
09 Nov 22 Q3 Sep 22 3 31 Dec 22 177.07 21.39 16.35 9.2% 0.00 1.72 2.6% 3.0% 0.2% 3.6%
16 Aug 22 Q2 Jun 22 2 31 Dec 22 181.74 21.47 16.31 9.0% 0.50 1.72 2.3% 16.9% 19.6% 6.0%
17 May 22 Q1 Mar 22 1 31 Dec 22 185.94 26.65 20.29 10.9% 0.00 2.19 27.8% 11.7% 29.1% 15.2%
15 Feb 22 Q4 Dec 21 4 31 Dec 21 145.44 17.13 15.72 10.8% 1.80 1.67 15.4% 8.5% 7.3% 3.0%
18 Nov 21 Q3 Sep 21 3 31 Dec 21 171.84 22.48 16.96 9.9% 0.00 1.80 10.6% 28.5% 10.2% 20.1%
17 Aug 21 Q2 Jun 21 2 31 Dec 21 155.44 20.20 15.39 9.9% 0.50 2.18 6.6% 8.4% 12.6% 4.5%
03 May 21 Q1 Mar 21 1 31 Dec 21 166.45 23.18 17.61 10.6% 0.00 2.49 24.1% 4.9% 8.8% 29.9%
22 Feb 21 Q4 Dec 20 4 31 Dec 20 134.09 20.47 16.19 12.1% 6.00 2.29 0.2% 2.7% 14.6% 34.6%
12 Nov 20 Q3 Sep 20 3 31 Dec 20 133.77 18.57 14.13 10.6% 0.00 2.03 6.7% 6.4% 4.1% 4.9%
13 Aug 20 Q2 Jun 20 2 31 Dec 20 143.33 19.39 14.73 10.3% 0.50 2.15 9.7% 1.5% 8.6% 5.8%
18 May 20 Q1 Mar 20 1 31 Dec 20 158.71 17.73 13.56 8.5% 0.00 1.98 15.2% 5.5% 12.7% 6.2%
13 Feb 20 Q4 Dec 19 4 31 Dec 19 137.75 13.94 12.03 8.7% 5.00 1.76 3.6% 19.1% 19.0% 16.3%
29 Nov 19 Q3 Sep 19 3 31 Dec 19 142.85 19.77 14.86 10.4% 0.00 2.20 1.8% 13.5% 6.8% 20.9%
30 Aug 19 Q2 Jun 19 2 31 Dec 19 145.47 18.32 13.92 9.6% 1.00 2.07 3.3% 17.3% 3.8% 34.6%
21 May 19 Q1 Mar 19 1 31 Dec 19 150.39 18.79 14.46 9.6% 0.00 2.19 30.1% 12.8% 0.7% 34.2%
18 Feb 19 Q4 Dec 18 4 31 Dec 18 115.63 17.66 14.37 12.4% 4.00 2.17 8.1% 3.0% 16.9% 21.1%
28 Nov 18 Q3 Sep 18 3 31 Dec 18 125.84 15.84 12.29 9.8% 0.00 1.86 1.5% 9.1% 18.8% 7.7%
26 Nov 18 Q2 Jun 18 2 31 Dec 18 123.99 12.91 10.34 8.3% 1.50 1.59 7.0% 5.9% 4.1% 7.1%
28 May 18 Q1 Mar 18 1 31 Dec 18 133.26 13.26 10.78 8.1% 0.00 3.82 18.7% 8.1% 9.2% 12.7%
28 Feb 18 Q4 Dec 17 4 31 Dec 17 112.25 12.82 11.87 10.6% 6.00 4.22 2.7% 51.6% 4.1% 19.6%
17 Nov 17 Q3 Sep 17 3 31 Dec 17 115.38 14.21 11.40 9.9% 0.00 3.99 1.4% 43.7% 18.1% 79.9%
25 Aug 17 Q2 Jun 17 2 31 Dec 17 117.05 12.64 9.65 8.2% 2.50 3.46 5.1% 47.9% 0.9% 114.4%
22 May 17 Q1 Mar 17 1 31 Dec 17 123.31 12.12 9.56 7.8% 0.00 3.43 66.6% 55.2% 3.6% 21.9%
24 Feb 17 Q4 Dec 16 4 31 Dec 16 74.03 6.30 9.93 13.4% 0.04 3.41 7.8% 17.2% 56.5% 35.3%
21 Nov 16 Q3 Sep 16 3 31 Dec 16 80.30 7.52 6.34 7.9% 0.00 2.23 1.5% 1.2% 40.8% 26.5%
22 Aug 16 Q2 Jun 16 2 31 Dec 16 79.14 7.72 4.50 5.7% 2.50 1.41 0.4% 40.5% 42.6% 23.0%
18 May 16 Q1 Mar 16 1 31 Dec 16 79.47 9.94 7.84 9.9% 0.00 2.81 11.1% 74.3% 48.9% 12.6%
23 Feb 16 Q4 Dec 15 4 31 Dec 15 89.40 17.53 15.34 17.1% 5.50 9.19 12.6% 75.2% 77.8% 37.9%
24 Nov 15 Q3 Sep 15 3 31 Dec 15 79.37 11.62 8.62 10.9% 0.00 5.17 41.0% 77.1% 47.5% 0.7%
25 Aug 15 Q2 Jun 15 2 31 Dec 15 56.31 8.41 5.85 10.4% 4.00 4.19 23.5% 38.6% 34.8% 22.2%
18 May 15 Q1 Mar 15 1 31 Dec 15 45.60 12.20 8.97 19.7% 0.00 6.43 10.6% 12.6% 19.3% 7.2%
24 Feb 15 31/12/14 4 31/12/14 51.02 13.92 11.12 21.8% 14.50 8.01 13.8% 11.6% 28.1% 19.4%

Historical Dividends

Financial Ratios

EPS 4.71 sen
Trailing PE (Sector Median: 18.3) 26.8
PEG 0.57
Altman Z 1.5
Beaver 0.001
Current Ratio 4.63
Debt-Equity (DE) Ratio 0.93
FCF Yield -0.32 %
Revenue QoQ 15.2 %
Revenue YoY -3.74%
Profit QoQ 79.69 %
Profit YoY -32.5 %
Profit Margin (Sector Median: 6.2) 6.5 %
ROE (ROIC: 3.91) 6.64 %
Dividend Per Share (DPS) 2.3 sen
Dividend Yield (DY) 1.83 %

Adjusted Financial Ratios

Ratios below have been recalculated after adjusting for One Off Gain/Loss detected from Quarterly reports

EPS
Trailing PE (Sector Median: 18.3)
Profit QoQ
Profit YoY
Profit Margin (Sector Median: 6.2)
ROE (ROIC: 4.11)
Altman Z

Fair Value

Weighted Average Fair Value:

Discounted Cash Flow (DCF) 5% Growth
Discounted Cash Flow (DCF) 10% Growth
Relative Valuation
Average Analysts FV based on 3 rating(s)
Graham Formula
Graham Number
Net Tangible Asset (NTA) 0.71
Consistent QR FV
The Fair Value numbers are not, and must not be construed to be, any recommendation, offer or invitation to buy or sell any securities, futures contracts or any other instrument. The figures shown here should be taken as educational purposes only

Advanced Calculators

Calculate the fair value of the stock based on expected growth / risk, contract / award value, forecasted profit or forecasted revenue.

Forward PE FV Calculator
Latest Profit (adjusted) [M] 15.28
Expected Profit (Next QR) [M]
Expected Profit (After QR above) [M]
Expected Profit (After QR above) [M]
Estimated Fair Value
Growth/Risk Fair Value Calculator
Expected growth (%)
Estimated downside / risk (%)
Estimated New DCF Fair Value
Contract/Award Contribution Calculator
Contract/Award Value (in Million)
Estimated Contribution to Stock Price
Estimated New DCF Fair Value
Profit-Based Calculator
Expected Profit (M)
for Year
Estimated New DCF Fair Value
Revenue-Based Calculator
Expected Revenue (M)
for Year
Estimated New DCF Fair Value
Market Pricing
Expected Profit (M) 461.63
Expected Revenue (M) 4254.63
Expected Growth (%) 31.0
The Fair Value calculated using this calculators are not, and must not be construed to be, any recommendation, offer or invitation to buy or sell any securities, futures contracts or any other instrument. The purpose of this tool is to help investor to quickly calculate their own expected Fair Value based on their own research

Directors Share Purchases (Beta)


No transaction in the last 2 months.

Summary


Market Cap: 1212 M.

Number of Shares: 961 M.

Adjusted Float: 47.0%.

Stock highly correlated with

KAWAN (93%)

WANGZNG (93%)

OMH (92%)

XIN (92%)

Duopharma Biotech Berhad, formerly known as CCM Duopharma Biotech Berhad. Duopharma core competencies in the pharmaceutical industry include manufacturing, research and development, and commercialization and marketing of over 300 generic drugs, including Omesec and Prelica, as well as Consumer Healthcare (CHC) products such as CHAMPS, FLAVETTES, PROVITON, and Uphamol, which are well-known and accepted by consumers in Malaysia, the region, and around the world. With technological and commercialization agreements with trustworthy and powerful international partners, the Company has also ventured into the biosimilars space.Their headquarters is located in Kuala Lumpur, Malaysia.

Sectors: Consumer Products, Healthcare, Pharmaceuticals, Post MCO, Vaccine

Code: 7148

Website: http://duopharmabiotech.com/

Related Links: Bursa | Annual Report | Announcement

Warrant Info:

No warrants listed

This calculator uses Malacca Securities (M+) cash upfront rate (min RM 8 or 0.08%) for all brokerage fee calculation.
This calculator uses Malacca Securities (M+) cash upfront rate (min RM 8 or 0.08%) for all brokerage fee calculation.